CGM is now considered the standard of care for people with T1D or for people with T2D receiving intensive insulin therapy, but evidence is accumulating supporting the benefits of CGM in T2D patients treated with basal or multiple-day insulin injections or initiating GLP-1 RA therapy [111]. The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.